Randomized, controlled trial of the clinical effect of selecrive SGLT2 blocker, ipragliflozin, and DPP-4 blocker in type 2 diabetic patients with NAFLD/NASH.- multicenter study
Not Applicable
- Conditions
- type 2 diabetic patients with NAFLD/NASH
- Registration Number
- JPRN-UMIN000015727
- Lead Sponsor
- Saga University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 55
Inclusion Criteria
Not provided
Exclusion Criteria
1.Ppatients with diabetes 2.Patients with past history of ovascular lesion or stroke 3.Patients with past history of allergy 4.Patients with the necessity of IRI therapy 5.Patients with past history of liver disorder or renal dysfunction 6.Inadequacy of usingig this therapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of patients decreasing of HbA1c>0.5% and not gaining weight gain 72 weeks after administration.
- Secondary Outcome Measures
Name Time Method